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Methamphetamine (MA) use disorder in individuals with severe mental disorders (SMDs) has significant 
impact on clinical presentation and care.  Although treatments exist, these are met by significant 
challenges. Notably, brief treatments for MA use within the general population have been feasible, 
acceptable and effective. An individualized, integrated treatment for MA use within a psychiatric 
inpatient setting would allow adjustment of the treatment according to individual patient needs. It is 
important to understand the patient needs and potential service barriers to care before formulating a 
treatment. This study begins to address this gap by seeking to understand the views of healthcare 
providers on a brief treatment to address MA use among patients with a dual diagnosis. 
METHODS:  
Thirteen key stakeholders working with patients with mental disorders including severe mental 
disorders and co morbid MA use were interviewed using an open-ended semi- structured interview 
schedule designed to explore their views on a brief treatment for MA use among patients with a dual 
diagnosis. Interviews were transcribed and the framework approach was used to conduct data analysis.  
RESULTS:  
Numerous themes emerged from the data. First, there are multiple risk factors for MA use. Second, this 
use has a significant impact on multiple aspects of patient presentation and care including individual 
impacts, family impacts, and impact on care. Third, although treatments for MA use disorders exist, 
these have significant challenges at multiple levels. Lastly, the integration of a modified brief treatment 
for MA use in patients with dual diagnosis would be possible if it was adjusted to patient-specific needs 
within the existing system and if the team adapting the treatment were cognizant of existing and 
potential challenges. 
CONCLUSIONS:  
The adaptation and integration of a brief treatment for MA use among patients with severe mental 
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CHAPTER 1: INTRODUCTION 
The prevalence of mental disorders is highly variable word wide with differing lifetime prevalence rates 
across various settings; from 12,0% in Nigeria to 47,4% in the United Sates (Kessler et al., 2007). More 
recently, a systematic review and meta- analysis from literature from 63 countries found that 17% of 
respondents worldwide reported a common mental disorder in the year preceding the assessment and 
29% of respondents had been identified as having a common mental disorder at some point in their 
lifetime (Steel, 2014). Within the South African context, the South African Stress and Health Study 
(SASH) found that mental disorders are highly prevalent with a lifetime prevalence of 30% (Herman et 
al., 2009; Tomlinson et al., 2016); with the most prevalent disorders being anxiety disorders (15.8%), 
substance disorders (13.3%) and mood disorders (9.8%). Furthermore, alcohol abuse (11,4%) was the 
most prevalent individual disorder (Herman et al., 2009). Although this study did not focus on severe 
mental disorders, psychotic symptoms were reported by 12,7% of respondents (Temmingh, Stein, 
Seedat, & Williams, 2011). These symptoms led to significant functional impairment and need for the 
use of mental health services (Temmingh et al., 2011). 
 
The most widely accepted definition of severe mental disorder (SMD) was proposed by The National 
Institute of Mental Health as a diagnosis of primary mental disorder  of at least two years duration 
which results in significant impairment (Ruggeri, Leese, Thornicroft, Bisoffi, & Tansella, 2000). Few 
studies have focused specifically on the prevalence of SMDs. A systematic review of the prevalence of 
schizophrenia drawn from 46 countries including South Africa, found the lifetime prevalence of 
schizophrenia to be 4,0 per 1000 (Saha, Chant, Welham, & McGrath, 2005), which is contrary to the 1% 
frequently quoted in the literature. SMDs result in significant impacts to mental health treatment 
services due to their prolonged duration and functional impairment. (Drake et al., 2001). Further, to 
complicate matters it is common for individuals with a SMD to also have a co-morbid substance use 
disorder; this comorbidity is often referred to as dual diagnosis (Drake et al., 2001).  
 
The definition of substance use disorder has varied from DSM IV TR to the more recent DSM 5. DSM IV 
TR previously divided  substance use disorder into abuse and dependence; as will be seen in literature 
pre DSM 5 (Hasin et al., 2013). DSM 5 shifted the definition of substance use disorder by combining 
abuse and dependence into a single entity, adding cravings as a criterion, dropping legal problems as a 
criterion and adding gambling disorder to the chapter “substance use and addictive disorders” (Hasin et 
8 
 
al., 2013). Thus, the DSM 5 definition of a substance use disorder is the persistent use of psychoactive 
substances despite adverse consequences (Association, 2013). This is characterized by symptoms of 
impaired control, social impairment, risky use and pharmacological properties including tolerance and 
withdrawal (Association, 2013). 
 
The prevalence of dual diagnosis varies across studies and populations. Johnson proposed that rates of 
dual diagnosis vary among patients with psychotic illness between 20% and 65%, with rates of 30% to 
50% among outpatients in the US. (Johnson, 1997). The European Schizophrenia cohort study 
investigated the rates of dual diagnosis among patients with schizophrenia in 9 centers across Europe 
and found that while France (19%) and Germany (21%) had low lifetime prevalence rates of dual 
diagnosis; the UK had a higher prevalence of 35% (Carra et al., 2012).  
 
People with an SMD use the same substances as the general population (Drake et al., 2001). In the 
Western Cape, clients accessing care for substance use most commonly report use of alcohol, cannabis 
and MA with MA  among the top two primary drugs used (Babor, Del Boca, & Bray, 2017). Therefore, 
individuals with a SMD in the Western Cape would be most likely to use MA, alcohol and cannabis due 
to their wide availability.  
 
A study completed at Stikland Hospital in the Western Cape, South Africa, found that half of patients 
presenting to acute mental health services over a three month period presented with co-morbid 
substance use (Weich & Pienaar, 2009). The most common substances used prior to admission were MA 
(13%), alcohol (23%) and cannabis (27%) (Weich & Pienaar, 2009). A multi- site South African study 
conducted in the Western Cape found that patients reporting MA use presenting with a variety of 
mental disorders including bipolar disorder (12%), schizophrenia (31%) and substance induced disorders 
(41%) (A Plüddemann et al., 2013). MA use is associated with multiple psychiatric symptoms including 
anxiety, mania, psychosis, aggression and cognitive impairment  (Rawson, Gonzales, & Brethen, 2002);  
(A Plüddemann et al., 2013). Substance use, including MA use also contributes to  medication non- 
adherence, recurrence of symptoms and readmission (Botha et al., 2010).  
 
At the present time there are no definitive, manualized treatments for management of substance use 
disorders among patients with dual diagnosis. Treatments that have been investigated vary in treatment 
approach and have employed a variety of techniques including psychoeducation, motivational 
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interviewing and a variety of cognitive behavioral interventions (Drake, O'Neal, & Wallach, 2008). These 
studies have been conducted in higher income countries. For example, a randomized control trial 
conducted in New South Wales, Australia compared a combined cognitive behavioral therapy and 
motivational interviewing brief treatment to treatment as usual for participants with a dual diagnosis 
who were using alcohol, amphetamine and cannabis (Baker et al., 2006). These participants were 
patients with non- acute symptoms receiving care as outpatients (Baker et al., 2006). Short term , the 
treatment demonstrated efficacy in decreasing psychiatric symptoms and substance use (Baker et al., 
2006). Long term, amphetamine users who received the treatment showed some stability of decreased 
use, whereas other long term effects were unremarkable (Baker et al., 2006).  
 
Screening, brief intervention, and referral to treatment (SBIRT) is an integrated, evidence-based 
treatment tool that aims to identify and reduce problematic substance use early (McCance-Katz, 2012). 
SBIRT can be delivered in a wide variety of settings (McCance-Katz, 2012). Screening aims to rapidly 
assess the severity of substance use and indicate the best level of treatment (McCance-Katz, 2012). Brief 
intervention is aimed at developing insight into substance use and to develop motivation to change 
(McCance-Katz, 2012). Referral to treatment is provides more extensive care for individuals screened 
with more severe substance use (McCance-Katz, 2012). Brief treatments exist along the SBIRT 
continuum as an intermediary between brief intervention and referral to treatment (Babor, 2017). Brief 
treatment is aimed at patients with higher severity of substance use and may requires more 
resources (Babor, 2017). Typically, brief treatment takes the form of a structured intervention 
comprising of five to twelve individual sessions drawing from motivational and cognitive- behavioral 
treatment modalities (Babor, 2017).  Within the Western Cape, several SBIRT programs have been 
implemented with success in a variety of settings including district hospitals (Sorsdahl, 2012); antenatal 
clinics (Sorsdahl, 2015); emergency centers (Sorsdahl, 2015) and primary care (Myers, 2019). However, 
significantly, none of these studies focused on SMDs and this is an immense gap that requires careful 
attention.  
A treatment targeted at patients with dual diagnosis who use MA is needed. However, as part of the 
process to identify and adapt an treatment, obtaining insights from key stakeholders is essential (Craig 




This study begins to address this gap by exploring the views of key stakeholders regarding a potential 
treatment for MA use among patients with SMDs.  
Study Aims 
To explore the views of key stakeholders on MA use amongst individuals with dual diagnosis, the current 
available treatments and views of a potential brief treatment to address MA use among patients with a 
dual diagnosis admitted to Valkenberg Hospital. 
Study Objectives 
1) To explore  the perceptions of MA use and dual diagnosis among key stakeholders 
2) To explore available treatments of MA and gaps in available services 
3) To explore stakeholders beliefs regarding brief treatments for MA use and suggestions for 
developing  a potential brief treatment to the needs of potential participants with dual diagnosis  
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CHAPTER 2: LITERATURE REVIEW 
This section will begin by providing an overview of SMDs with a focus on dual diagnosis. It will then 
describe MA and its use in South Africa. Evidence based treatments for MA use disorders and dual 
diagnoses are then described in detail.    
Severe Mental Disorders  
The National Institute of Mental Health defines SMDs as a diagnosis of primary mental disorder causes 
significant functional impairment and require at least two years of treatment (Ruggeri et al., 2000). 
Usually this includes illnesses such as schizophrenia, schizoaffective disorder, bipolar disorder and major 
depressive disorder. However, definitions vary in multiple ways with regards to the inclusion or 
exclusion of personality disorders, duration of illness and measurement of disability (Ruggeri et al., 
2000): This variation in definition of severe mental disorder leads to difficulty in estimation of 
prevalence rates of severe mental disorders; which will in turn impact on planning of service provision. 
(Ruggeri et al., 2000).  
 
Mental disorders are highly prevalent worldwide with differing lifetime prevalence rates across various 
settings; from 12,0% in Nigeria to 47,4% in the United Sates (Kessler et al., 2007). More recently, a 
systematic review and meta- analysis from literature from 63 countries found that 17% of respondents 
worldwide reported a common mental disorder in the year preceding the assessment and 29% of 
respondents had been identified as having a common mental disorder at some point in their lifetime 
(Steel, 2014). Mental disorders are highly prevalent in South Africa with a lifetime prevalence for 
common mental disorders of 30% according to the South African Stress and Health (SASH) Study 
(Herman et al., 2009; Tomlinson et al., 2016). Although the SASH study did not focus on SMDs, one arm 
of the study evaluated the prevalence of psychotic symptoms at 12,7% (Temmingh et al., 2011). These 
symptoms were associated with increased functional impairment and increased use of mental health 
services (Temmingh et al., 2011).  
 
However, few studies have reported on the prevalence of SMDs. A systematic review of the prevalence 
of schizophrenia drawn from 46 countries including South Africa, found the lifetime prevalence of 
schizophrenia to be 4,0 per 1000, which is contrary to the 1% frequently quoted in the literature (Saha 
et al., 2005). The prevalence of bipolar disorder is estimated at  1% (Grande, Berk, Birmaher, & Vieta, 
2016) and it is considered as among the top twenty leading causes of disability worldwide (Ferrari et al., 
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2016).  A study conducted in South London examined the co morbidity of alcohol and other drugs 
among people with psychotic disorders and found that the one year prevalence rate for all substances 
was 36% with 31% for alcohol and 15% for other drugs (Menezes et al., 1996),  
 
In spite of this difficulty estimating the prevalence of SMDs, SMDs place a large burden on society 
worldwide (Drake et al., 2001). It is estimated mental disorders including depression, substance use, 
dementia, bipolar disorder and schizophrenia contribute to 13% of the global burden of disease (Collins 
et al., 2011). Mortality and morbidity rates among individuals with SMDs are high with mortality 
occurring 10 to 20 years sooner than among the general population (Liu et al., 2017).This increase in 
mortality rates can be due to natural and unnatural causes (Liu et al., 2017). Natural causes include 
preventable physical diseases such as cardiovascular disease, respiratory disease, diabetes mellitus, 
cancers and infections (Liu et al., 2017). Unnatural causes include suicide, homicide and accidents (Liu et 
al., 2017).  
 
There are multiple negative implications of living with an SMD.  These implications include lower 
education attainment; unemployment and reliance on social grants; homelessness; incarceration; 
stigma and caregiver burden (Insel, 2008). Mental illness leads to poorer school performance and higher 
rates of school dropout (Freudenberg & Ruglis, 2007). Lower levels of education in turn lead to an 
increase in health risk behaviors such as smoking and other substance use (Freudenberg & Ruglis, 2007). 
School dropout has been associated with worsening mental and physical health, lower attained 
education and higher levels of unemployment and reliance on social grants (Freudenberg & Ruglis, 
2007). Unemployment is a consequence of both mental disorders and incomplete education (Collins et 
al., 2011), (Freudenberg & Ruglis, 2007). Typically more than 85% of people living with SMI are 
unemployed (Goldberg et al., 2001). Early illness onset, worsening illness severity and recurrent 
admissions impact negatively on employment rates (Goldberg et al., 2001). Vocational programs have 
been formulated to mitigate unemployment but these may be inaccessible or under-utilized (Goldberg 
et al., 2001). A qualitative study from Boston University examined the impact of employment among 
people living with SMI and found that employment provides meaning, promotes self-esteem, assists 
with management of symptoms and provides financial means (Dunn, Wewiorski, & Rogers, 2008). 
Conversely, unemployment can be seen to do the opposite: worsening self-esteem and coping 
mechanisms and leading to significant financial impacts. Further sequelae of SMD include criminal 
activity and homelessness (Draine, Salzer, Culhane, & Hadley, 2002). Risk factors for incarceration 
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include lower levels of education, substance use, unemployment and lack of financial means (Draine et 
al., 2002). These have already been discussed as sequelae of SMD; this leads to a high number of people 
with SMI within prison populations where they may be victims of assault and violence (Draine et al., 
2002). Incarceration in turn can also lead to worsening stigma and impact negatively on the 
aforementioned consequences of SMD.  Homelessness can be a consequence or a cause of mental 
illness (Perry & Craig, 2015). Rates of homelessness vary among social settings (Draine et al., 2002). 
There are increased prevalence rates of SMI, personality disorders, suicide and self-harm among the 
homeless (Perry & Craig, 2015). A systematic review of mental illness among the homeless living in 
Higher Income Countries found significant rates of mental illness including alcohol use disorders (8,1-
58,5%), other substance use disorders (4,5-54,2%) and psychotic disorders (2,8-42,3%) (Fazel, Khosla, 
Doll, & Geddes, 2008).There is limited data for prevalence rates of homelessness in LMIC. In LMIC 
homelessness has been a consequence of de-institutionalization and decentralization of mental health 
services leading to neglect (Saraceno et al., 2007). Homelessness itself leads to increased morbidity and 
mortality rates and higher utilization of services (Hwang, 2001).  
 
Stigma of living with a mental illness is an additional burden faced by those living with an SMI (Gaebel, 
Zäske, & Baumann, 2006). Stigma is impacted by both the perceptions of the public and the perceptions 
of people living with SMI (Gaebel et al., 2006). It has the ability to worsen mental illness by reducing 
quality of life, limiting social interactions, limiting opportunities and reducing self-esteem (Gaebel et al., 
2006) . It also impacts help- seeking behavior regarding health care through system barriers and 
personal barriers (Corrigan, Druss, & Perlick, 2014). System barriers include negative attitudes from 
health care staff, financial barrier which impact access to care and workforce barriers which impact 
employment (Corrigan et al., 2014). Personal barriers are attitudes that affect treatment seeking 
behavior and include poor recognition of early symptoms, treatment avoidance, treatment dropout and 
lack of an appropriate support structure (Corrigan et al., 2014). 
 
Caregiver burden is another consequence of SMI as people living with SMI may require long term care 
and the family take responsibility for this (Mulud & McCarthy, 2017). Provision of long term care can 
affect caregivers mentally and physically (Mulud & McCarthy, 2017). Burden is impacted by multiple 
factors such as family understanding of the illness, other socioeconomic burdens and illness severity 
(Saunders, 2003). Burden can be objective or subjective. Objective burden is defined as the negative 
effects of the mental illness on the family plus the stress of caring for an individual with an SMD 
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(Baronet, 1999). Subjective burden is the subjective feelings and thoughts held by the caregiver about 
caring for a person with SMI (Baronet, 1999). Mechanisms to alleviate burden include supportive social 
support networks (Saunders, 2003) 
 
Further, to complicate matters, one of the most common comorbidities for individuals with SMDs is 
substance use disorders. This is referred to as a dual diagnosis (Drake et al., 2001).  
 
Dual Diagnosis 
Dual diagnosis is defined as the co-occurrence of a SMD with a substance use disorder (Mueser, Drake, 
& Wallach, 1998). There are four proposed etiologies of dual diagnosis (Mueser et al., 1998). First, 
substance use can result in a mental disorder in an individual who would have remained well in the 
absence of substance use (Mueser et al., 1998).  Second, the presence of an SMD increases the risk of 
substance use for multiple reasons including management of symptoms, side effects or stigma (Mueser 
et al., 1998). Third, the SMDs and substance use disorders may share risk factors such as genetic risk 
factors (Mueser et al., 1998). Lastly each disorder can precipitate the other (Mueser et al., 1998).  
 
Dual diagnosis compounds medical, psychological and social challenges discussed previously which leads 
to worsening prognosis and further treatment complexities.  Medical challenges include increased 
severity of symptoms including aggression and suicidality; increased high risk behaviors which may lead 
to infections including HIV and treatment non- compliance leading to multiple relapses and 
readmissions  (Miles et al., 2003; Mueser et al., 1998).Psychosocial challenges faced  include impacts to 
the individual, their family and community such as loss of employment, homelessness, legal difficulties, 
family emotional and financial distress and increased caregiver burden (Miles et al., 2003; Mueser et al., 
1998). 
 
The prevalence of dual diagnosis varies worldwide with current rates of 12-64% and lifetime prevalence 
rates of 12-65% (Weich & Pienaar, 2009).  Although epidemiological data in South Africa is limited, a 
study conducted at Stikland Hospital in 2008 estimated that half of participants admitted to the acute 
psychiatric services over a 3-month period with SMDs presented with a dual diagnosis. A second South 
African study conducted at 6 hospitals in Cape Town, Western Cape found that patients admitted with 
MA use disorder presented with comorbid substance induced psychosis (41%), schizophrenia (31%) and 
bipolar disorder (12%) (A Plüddemann et al., 2013). Typically, individuals with SMDs used the same 
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substances as individuals in the general population  (Drake et al., 2001). Within the Western Cape 
alcohol, cannabis and MA are the most common substances used (J. E. Siphokazi Dada, Nadine Harker 
Burnhams,, Charles Parry, & Kitshoff, 2015). Recent data suggests that in South Africa, specifically the 
Western Cape, the prevalence of SMDs may be increasing due to the MA epidemic. 
Methamphetamine and Its Use in South Africa 
According to The World Drug Report of 2019, approximately 5,5% of the world’s population have used 
drugs at least once (UNODC, 2019). Stimulants, including MA, are among the most common drugs used 
worldwide  (UNODC, 2019). The type of stimulants used vary according to country and it has been 
reported that MA use is increasing in several countries (UNODC, 2019). 
 
In South Africa, MA use emerged post- Apartheid due to a confluence of social, economic and political 
influences (Watt et al., 2014). MA is now widely available within the Western Cape and poses significant 
burden to both mental health and substance use treatment systems (Pasche & Myers, 2012). According 
to the South African Community Epidemiology Network on Drug Use (SACENDU)  Brief of 2019, 
admissions to treatment facilities for MA use is high within the Western Cape with 28% of patients 
admitted to rehabilitation centers reporting MA as their primary substance (N. H. B. Siphokazi Dada, 
Jodilee Erasmus, Warren Lucas, Charles Parry, Arvin Bhana, Sandra Pretorius, Roger Weimann, TB HIV 
Care, Anova Health Institute, OUT Wellbeing & the University of Pretoria, 2019). Most MA users report 
smoking it as opposed to injecting (N. H. B. Siphokazi Dada, Jodilee Erasmus, Warren Lucas, Charles 
Parry, Arvin Bhana, Sandra Pretorius, Roger Weimann, TB HIV Care, Anova Health Institute, OUT 
Wellbeing & the University of Pretoria, 2019). MA uses poses a significant burden to treatment centers; 
a South African study published in 2009 examined the SACENDU surveillance data and found a dramatic 
increase in treatment admissions from 2004 to 2006 (Andreas Plüddemann, Plüddemann, Myers, & 
Parry, 2008). 
 
Several South African studies conducted in adolescents have discussed impacts of MA. First, MA use in 
high school students was associated with aggressive behavior, other substance use especially tobacco 
and alcohol, and depression (A. Plüddemann, A. J. Flisher, R. McKetin, C. Parry, & C. Lombard, 2010). 
Another study completed with high school students in the Western Cape found that students using MA 
reported more school absenteeism than their non-substance using classmates (A. Plüddemann, A. J. 
Flisher, R. McKetin, C. D. Parry, & C. J. Lombard, 2010). Lastly, a third study conducted among high 
school students in Cape Town, South Africa found that MA use was associated with risky sexual behavior 
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which adds to concern regarding HIV transmission rates among adolescents (Andreas Plüddemann, 
Flisher, McKetin, Parry, & Lombard, 2012) 
 
Multiple psychiatric symptoms and syndromes have been associated with MA use; including psychotic 
symptoms, mood symptoms, anxiety symptoms, neurovegetative shift, increased aggression and 
cognitive impairment (Rawson et al., 2002), (A Plüddemann et al., 2013). A South African study 
examined  one hundred MA users and found high rates of psychiatric comorbidity (36%) including mood 
disorders (16%), psychotic disorders (13%) and anxiety disorders (13%) with 25% of these disorder being 
substance induced (Akindipe, Wilson, & Stein, 2014).  Symptoms of MA psychosis include delusions, 
auditory hallucinations and increases in aggression and impulsivity (Maxwell, 2005).  MA use disorder 
leads to Cognitive impairments including attention and concentration, memory deficits and  executive 
function; which carry negative effects for treatments for MA use (Barr et al., 2006a) (Potvin et al., 2018).  
 
It may be difficult to differentiate between MA induced psychosis and a primary psychotic disorder with 
comorbid MA use as symptoms are similar (Glasner-Edwards & Mooney, 2014).  Several risk factors are 
associated with the development of a MA induced psychosis including dose, duration and route of use in 
addition to underlying personal risk factors (Fasihpour, Molavi, & Shariat, 2013). Differentiating between 
a MA induced psychosis and existing primary psychotic or bipolar disorder is not determined by 
symptomatology (Fasihpour et al., 2013) but rather requires a clear historical timeline and possible 
toxicology (Glasner-Edwards & Mooney, 2014).  
Treatment of Mental Disorders  
Given the high prevalence and significant impact of mental disorders worldwide, the World Health 
Organization proposes a model describing a variety of mental health services which emphasizes multiple 
levels of collaborative care. (WHO 2009).   
 
The model recommends that countries use this a framework to guide how they structure how they 
configure their mental health services to include self-care; informal community services; primary care 
based mental health services; general hospital based mental health services and limited dedicated 
psychiatric hospitals (see figure 1) (WHO 2009). Lower tier services should be widely utilized but at 
lower costs; and higher tier specialist services, although costly, should be used by a much smaller 







Figure 1: World Health Organization Service Organization Pyramid for an Optimal Mix of Services for 
Mental Health 
 
South Africa is a middle income country with high rates of poverty, unemployment and socio economic 
inequalities (Burns, 2011). It is also challenged by high levels of crime and violence, is the epicenter of 
the HIV pandemic and has high levels of substance use (Burns, 2011). All these factors influence mental 
health and the development of mental disorders (Burns, 2011). 
Within South Africa, health services are divided into private and public, with the public health sector 
serving the majority of the population (Docrat, Besada, Cleary, Daviaud, & Lund, 2019). Therefore, 
provision of mental health services has been met with multiple barriers including lack of resources (Jack 
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et al., 2014). Furthermore, existing resources are concentrated in tertiary settings with fewer resources 
in primary and community care levels (Jack et al., 2014).   
 
Primary health care is responsible for early identification and management of mental disorders, 
maintenance of well individuals living with chronic mental disorders and appropriate referral to higher 
levels of care as needed plus health prevention and health promotion activities (WHO 2009). These 
allow for affordable, accessible and acceptable treatment of common mental disorders to be integrated 
with care for stable physical conditions (WHO, 2009). Within LMIC such primary health care systems 
may vary in quality and reach (Alem, Jacobsson, & Hanlon, 2008).  In South Africa, several challenges 
have been posed to the integration of mental health services into primary care including paucity of 
financial and human resources (Tomlinson et al., 2016). Integrating care into primary care level in South 
Africa requires strengthening the system including staff training and support, improving availability of 
resources such as medication and availability of psychosocial treatments (Thornicroft et al., 2018). 
 
Community mental health services include a multitude of services such as group homes, family 
assistance, home based care practitioners, mobile clinics, residential homes, rehabilitation services and 
day centers (WHO, 2009). These services are essential to prevent hospital admission, support 
deinstitutionalization and improve treatment outcomes (WHO, 2009). Within LMIC this service could 
possibly be provided by linking traditional healers, families and religious organizations with primary 
health services (Alem et al., 2008). Within South Africa, a study conducted in Kwazulu-Natal revealed 
that although most patients held traditional, cultural beliefs around mental disorders; there were 
several attitudinal barriers to collaboration between traditional healers and westernized health care 
providers (Campbell-Hall et al., 2010). These would need to addressed to allow for better community 
level service collaboration (Campbell-Hall et al., 2010) 
 
Within general hospital settings, the integration of mental health care is essential because hospital 
admissions may be required for people with mental disorders (WHO, 2009). District hospitals are usually 
accessible and acceptable for treatment of both physical and mental disorders (WHO, 2009). These 
facilities can refer people with mental disorders who require higher levels of care to tertiary services 
(WHO, 2009). Within African countries, most mental health practitioners are within urban settings 
including tertiary hospitals, with fewer practitioners located in rural and district settings (Alem et al., 
2008). Services may also be concentrated within the private sector instead of the public  sector (Alem et 
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al., 2008). Within South Africa, general hospitals are utilized for the involuntary admission of patients for 
72 hour assessment under the Mental Health Care Act (Petersen & Lund, 2011). Some of the challenges 
faced within these district hospitals are a lack of specialist infrastructure and staffing (Petersen & Lund, 
2011). 
 
Specialist psychiatric care should be required to manage a minority of people with mental disorders who 
present with complex disorders or require a longer duration of treatment (WHO, 2009). Improving the 
level of care available at district hospitals is one mechanism for decreasing the need for these services 
(WHO 2009). However, the majority of mental health resources are concentrated at tertiary level within 
South Africa (Jack et al., 2014). Policy shifts towards deinstitutionalized care has led to a decrease 
number in tertiary inpatient beds and early discharges of patients to compensate for this (Petersen & 
Lund, 2011). This has led to the development of high frequency users due to early discharges, treatment 
non- compliance and substance use (Petersen & Lund, 2011). 
Treatment of Methamphetamine Use Disorders 
The World Health Organization Mental Health Gap guidelines for the management of substance use 
disorders recommend the use of a valid screening tool to screen for substance use disorders (Dua et al., 
2011). Patients with mild and moderate substance use disorders should receive a brief intervention 
(Akindipe et al., 2014). Patients with moderate to severe use should be referred to definitive substance 
treatment services which may be either outpatient, intensive outpatient or inpatient (Dua et al., 2011). 
Screening tools and treatment modalities may depend on which substances are used (Dua et al., 2011). 
Screening, brief intervention, and referral to treatment (SBIRT) is an integrated, evidence-based 
treatment tool that aims to identify and reduce problematic substance use early (McCance-Katz, 2012). 
SBIRT can be delivered in a wide variety of settings (McCance-Katz, 2012). Screening aims to rapidly 
assess the severity of substance use and indicate the best level of treatment (McCance-Katz, 2012). Brief 
intervention is aimed at developing insight into substance use and to develop motivation to change 
(McCance-Katz, 2012). Referral to treatment is provides more extensive care for individuals screened 
with more severe substance use (McCance-Katz, 2012). Within the Western Cape, several SBIRT 
programs have been implemented with success in a variety of settings including district hospitals 
(Sorsdahl, 2012); antenatal clinics (Sorsdahl, 2015); emergency centers (Sorsdahl, 2015) and primary 
care (Myers, 2019). However, significantly, none of these studies focused on SMDs and this is an 
immense gap that requires careful attention. Brief treatments exist along the SBIRT continuum as an 
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intermediary between brief intervention and referral to treatment (Babor, 2017). Brief treatment is 
aimed at patients with higher severity of substance use and may requires more resources (Babor, 
2017). Typically, brief treatment takes the form of a structured intervention comprising of five to 
twelve individual sessions drawing from motivational and cognitive- behavioral treatment 
modalities (Babor, 2017).   
Psychosocial treatments are the preferred mode of treatment of MA use as pharmacological treatment 
of MA use disorders have been shown to have limited effectiveness (Lee, Lee, Rawson, Lee, & Rawson, 
2008). Multiple psychosocial treatments exist for the management of MA use disorders (J. Shearer, 
2007), including cue exposure, contingency management (J. Shearer, 2007), the 12 step programs, 
motivational interviewing techniques and cognitive behavioral treatments (J. Shearer, 2007). However 
engagement in psychosocial treatment is challenging, due to low rates of treatment seeking and 
retention (Courtney & Ray, 2014). The latter three psychosocial treatments will be described in more 
detail given their relevance to the proposed study.  
 
Self-help treatments such as alcoholics anonymous are part of the widely available twelve step 
programs for substance use disorders (Donovan & Wells, 2007). The twelve step approach 
conceptualizes addiction as  a pervasive disease, developing self- awareness and whilst assisting others 
in their recovery (Donovan, Ingalsbe, Benbow, & Daley, 2013). Twelve step programs are usually utilized 
as a form of treatment maintenance following other evidence- based treatments for MA use (J. Shearer, 
2007). Usually, substance using individuals engage with twelve step programs during the initial phases of 
treatment or for post- treatment support (Donovan & Wells, 2007).  
 
Motivational interviewing is a client-centered, directive therapeutic approach which explores and 
resolves ambivalence in an attempt to modify  substance using behavior (Hettema, Steele, & Miller, 
2005). Motivational interviewing is effective in supporting treatment retention during the early phases 
(Carroll et al., 2006). 
 
Cognitive behavioral therapy (CBT) has been adapted for the management of a wide variety of mental 
disorders including substance use disorders (J. Shearer, 2007). Within this model substance use is 
viewed as a maladaptive behavior due to underlying irrational beliefs about the self, others and the 
environment (McHugh, Hearon, & Otto, 2010; J. Shearer, 2007). Multiple different approaches exist and 
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include a functional analysis of underlying thoughts and emotions related to substance use; 
identification of triggers, thought stopping techniques and relapse prevention skills (McHugh et al., 
2010). CBT has been shown to be effective in reducing substance use including stimulant use (J. Shearer, 
2007). An Australian study compared a CBT- based brief treatment to abstinence based treatment found 
that the CBT treatment was superior (Baker, Kay-Lambkin, Lee, Claire, & Jenner, 2003). A South African 
randomized control trial demonstrated that a problem solving treatment was effective to decrease 
substance use (K Sorsdahl, DJ Stein, et al., 2015). 
 
Relapse prevention is a cognitive behavioral technique that aims to teach effective management of high 
risk situations through use of  behavioral skills training and cognitive methods (Marlatt & George, 1984); 
and therefore prevent relapse (J. Shearer, 2007). Relapse prevention has been adapted for a variety of 
trails and has been found effective in managing MA use (Kobayashi et al., 2007); (Matsumoto et al., 
2014); (Tanibuchi et al., 2016) 
 
Contingency management is a behavioral treatment where incentives are provided for cessation of  
substance use or other behaviors directed at recovery (James Shearer, 2007). It is considered effective 
for the management of MA use (Roll, 2007) and has demonstrated superiority over treatment as usual in 
promoting abstinence both short term, whilst receiving incentives; and long term post contingency 
management treatments (Roll et al., 2006). A South African study found that contingency management 
was effective in reducing MA use among MA users living in Cape Town (Okafor et al., 2019). 
 
The Matrix Model is an outpatient- based substance treatment approach that has been assessed for 
management of stimulant use including MA (Magidson et al., 2017). It is rooted in cognitive behavioral 
approaches and draws on a variety of techniques to promote and maintain abstinence, and to educate 
and support individuals and their families (Rawson et al., 2002). Limited data exits regarding 
implementation among MA users with comorbid psychosis (Barr et al., 2006a). Within the Western 
Cape, the City of Cape Town implemented Matrix Model outpatient treatment services at primary health 
care clinics to offer affordable, accessible and evidenced-based services to people with 
methamphetamine use disorder (Gouse et al., 2016). However, one study revealed that there are still 
treatment barriers as only 13% of people who initiate treatment, complete the entire 16 week program 




Treatment of MA use poses several challenges (Meade et al., 2015). MA users’ experiences and 
perceptions of treatment influence treatment engagement as shown by a Western Cape study (Meade 
et al., 2015). First, although most users had not attended treatment, they held negative perceptions of 
treatment facilities as punitive, hostile, and ineffective (Meade et al., 2015). Second Most of these 
participants expressed motivation to quit (Meade et al., 2015). Lastly, most users stated that the social 
environment where methamphetamine is highly accessible and use is normalized was the biggest barrier 
to quitting (Meade et al., 2015). A second study conducted in Cape Town examined structural barriers 
for treatment of substance use disorders in previously disadvantaged communities and found 
fragmented service delivery; poor capacity and other infrastructural concerns; and limited resource 
allocation to treatments which limits affordable and accessible services (Bronwyn Myers, Louw, & 
Fakier, 2008). A third study conducted in Cape Town examined gender differences in barriers to 
substance treatment and found that women experienced more barriers to treatment including 
awareness of treatment options; accessibility and affordability of these treatments which led to 
negative impacts on treatment (B Myers, Louw, & Pasche, 2011). A fourth study from Cape Town 
examined barriers to treatment among black and colored South Africans and found that these 
populations had less awareness of available treatment options and decreased accessibility to treatment 
(Bronwyn Myers, 2013). These barriers were even more pronounced among the black South African 
population (Bronwyn Myers, 2013). 
Treatment of Dual Diagnosis 
Comprehensive treatment of dual diagnosis requires the treatment of both SMD and substance use 
disorder (Drake et al., 2008). Traditionally mental disorders are treated with a combination of 
pharmacological and psychosocial treatments. For severe mental disorders this treatment usually occurs 
in an inpatient setting and is delivered by mental health professionals including psychiatrists(Drake et 
al., 2001). In the South African context, the burden of treatment of SMDs falls on mental health services 
within government hospitals. The treatment of substance use disorders is usually delivered by drug 
treatment centers or self-help groups such as alcoholics anonymous which rely heavily on twelve step 
approaches (H. T. B. Myers, 2012). In South Africa, this is coordinated by the Department of Social 
Development (H. T. B. Myers, 2012).  
 
Integrated treatment for dual diagnosis encompasses simultaneous treatment of both disorders by one 
team with the prerequisite skills for managing both disorders (Drake et al., 2001). This treatment 
facilitates improved patient outcomes (Drake et al 2001). Integration of treatment promotes treatment 
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accessibility of services (Murthy & Chand, 2012).  A large, multi-site Methamphetamine Treatment 
Project in conducted in parts of the United States examined co- occurring psychiatric symptoms among 
1061 MA users  and found high rates of comorbidity (Zweben et al., 2004). In this study setting, 
community-based programs were aimed at substance use management only and were therefore ill- 
equipped to managed comorbid mental disorders (Zweben et al., 2004). Conversely, mental health 
treatment programs focused mostly on care of mental disorders and not management for substance use 
(Zweben et al., 2004).  These findings support the integration of treatment for this population (Zweben 
et al., 2004).  
 
Management of dual diagnosis is met with multiple challenges. First, treatments are usually offered by 
two separate systems; and integrated services, if they exist, are costly. (Drake et al., 2001).  Second, 
substance use treatment programs may not be equipped to manage individuals with comorbid mental 
disorders.  (Mueser et al., 1998).  Conversely, mental health treatment teams may not possess the skills 
required for management of substance use disorders. (Drake et al., 2001). This results in service 
fragmentation and delivery of incomplete care (McGovern, Lambert-Harris, Gotham, Claus, & Xie, 
2014)Third, illness related factors may impact on individual participation in existing substance use 
treatment programs (Drake et al., 2001). These factors include a variety of mental disorder symptoms 
such as positive psychotic symptoms  (Morris, Griffiths, Le Pelley, & Weickert, 2013); negative psychotic 
symptoms (Blanchard & Cohen, 2006); mood symptoms and cognitive impairment (Harvey et al, 2005). 
 
There are no definitive, manualized psychosocial treatments for treatment of substance use disorders 
among patients with dual diagnosis. At present, a variety of treatments have been used and include 
psychoeducation, motivational interviewing and cognitive behavioral techniques utilized in individual or 
group settings  (Drake et al., 2008) 
 
A few studies have been conducted in higher income countries. For example, a randomized control trial 
conducted in New South Wales, Australia compared a brief  blended motivational interviewing and 
cognitive behavioral treatment to treatment as usual for participants with a dual diagnosis who were 
using alcohol, cannabis and amphetamine (Baker et al., 2006). These participants were patients with 
non- acute symptoms treated as outpatients in the community. (Baker et al., 2006). Short term , the 
treatment demonstrated efficacy in decreasing psychiatric symptoms and substance use (Baker et al., 
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2006). Long term, amphetamine users who received the blended treatment showed some stability of 
decreased use, whereas other long term effects were unremarkable (Baker et al., 2006). 
 
Given the prevalence of MA use within the Western Cape and the impact that MA has for individuals, their 
families and on treatment approaches and systems; there is a potential need for an integrated treatment. 
Prior to developing and testing a brief treatment, formative work is required in order to increase its 
acceptability and feasibility (Craig et al., 2008). Therefore, our study aims to assess the views of healthcare 
providers and potential participants on a possible brief treatment for MA use among patients with a dual 
diagnosis. This could be an important first step in the development of an acceptable, feasible and effective 







CHAPTER 3: METHODS 
Participants 
Thirteen healthcare providers working with patients with dual diagnosis were interviewed. They 
included psychiatrists, psychologists, social workers, and occupational therapists from a variety of 
institutions that included both district and tertiary settings working with both adolescent and adult 
patient populations. Most participants were psychiatrists (N=5), followed by occupational therapists 
(N=3), social workers (N=3) and clinical psychologists (N=2). 
Recruitment:  
Stakeholders were recruited from tertiary and district psychiatric inpatient treatment settings within the 
Western Cape. Fifteen stakeholders were approached to participate in this study, however two were 
unable to participate. Thirteen stakeholders agreed to participate, and saturation was reached at 10 
participants. Stakeholders included healthcare providers presently providing care for patients with a 
dual diagnosis and MA use, key management at psychiatric facilities and substance use specialists.  
Procedure: 
Participants were contacted via email to determine willingness to participate in this study. The study 
was explained and a convenient time to conduct an in depth, semi- structured interview was identified. 
At the interview, informed consent was obtained (Appendix A) and the interview was conducted by the 
first author following the semi- structured interview schedule formulated for this study (Appendix B). 
These interviews were conducted in a quiet, confidential space in English, although Afrikaans- speaking 
participants were able to express themselves in Afrikaans if desired as this is a language spoken and 
understood by the investigator. These interviews were conducted over a 7-month period from February 
to August 2018. Interviews were recorded and stored on a password protected device. Participants are 
identified by a study number. No remuneration was offered for participation in this study. 
 
Data Analysis  
The recorded data was transcribed by a UCT approved transcription service and the transcripts stored on 
a password protected computed accessible to only the investigator. These transcripts were then analyzed 
using the framework approach (familiarization, identifying a thematic framework, indexing, charting, 
mapping, and interpretation of the data). Initially, interview transcriptions were read for emergent 
themes, which were then coded. Care was taken to ensure that the codes accurately captured the 
respondent’s meaning. Two investigators assessed the data independently and came to an agreement 
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regarding the coding list and interpretation of the data. The NVivo 12.0 software program was used for 
data analysis.  
 
Ethical Considerations 
The ethical standards prescribed by the Committee for Human Research of the University of Cape Town 
were strictly adhered to. Ethics approval was granted by the Committee for Human Research of the 
University of Cape Town (743/2017). If consent was required by facilities where stakeholders are 
employed, it was sought from the Western Cape Department of Health.  
Informed Consent 
This study was explained in full to all potential participants. Emphasis was placed on voluntariness of 
participation.  Written informed consent was obtained from those who agree to participate. Those 
unwilling to participate were not coerced. Although this study placed no physical risks to participants, 
the semi- structured nature of qualitative studies may raise potentially sensitive or emotionally 
triggering topics. Therefore, all participants were alerted to the potential of this risk and reassured that 
they would be able to terminate the interview at any point or to leave the study if this were desired. If 
topics were triggering, this could be discussed in depth with the researcher who would provide 
containment. No participants wished to terminate interviews or to withdraw from the study. Further 
potential risks in qualitative studies include the potential that participants may be identified. 
Participants were aware of this potential risk but felt that the views expressed were views shared by 
most mental health practitioners at facilities within the Western Cape.  
Confidentiality and Data Management 
Participant signatures were recorded on consent forms, but the consent forms and all other measures 
contained no further form of identifying data. Numbers were used to identify each stakeholder within 
the demographic data capture sheet. These numbers were used within the qualitative data 
transcriptions. The transcriber was approved of by UCT and signed a confidentiality agreement before 
transcriptions were initiated. Digital recordings were destroyed after the transcription was complete. 
The transcriptions were saved to a desk top computer that is password protected. After 5 years, these 





CHAPTER 4: RESULTS 
Results are organized according to the themes derived from the interviews.  Specifically, these include 1) 
Perceived risk factors for methamphetamine (MA) use; 2) Perceived impact of methamphetamine use; 
3) Available treatments for MA use and gaps in available services; 4) A potential brief treatment for MA 
use among patients with SMDs. 
1. Perceived Risk Factors for Methamphetamine Use 
Several risk factors were described by stakeholders (N=5) including easy access and normalization of 
use; high levels of stress and adversity within the communities; comorbidity such as depression and 
anxiety; low educational attainment and unemployment and a perceived lack of meaning. Adolescents 
and women were thought to be particularly vulnerable populations as described by one participant who 
said: 
They have a huge trauma background so sexual abuse, domestic violence and they are using the 
cannabis to treat their anxiety and mandrax to come down from the meth. So the different roles the 
women play, they feel like their psychiatric meds slows them down. And a lot of women when I 
speak to them, they actually enjoy being manic because they get a lot of things done. You know, so 
they are able to go to work from five in the morning when they need to leave home and come back 
at six in the evening. They go and do domestic work or they work in retail or whatever. They are able 
to look after six children, you know. They are able to juggle all these things using substances. 
(Participant 8, social worker) 
Further, patients with mental disorders were thought to be vulnerable to MA use as they may have 
preexisting mental health symptoms or medication induced side effects that they choose to medicate 
with MA for temporary relief: 
And I think a lot of the patients are using Tik because obviously they want that energy. A lot of the 
patients also say they feel slow because of the psychiatric medication or they want something to 
just make them feel a bit more perked up. (Participant 13, occupational therapist) 
2. Perceived Impact of Methamphetamine Use 
All stakeholders (N=13) felt that MA had an impact on multiple aspects of patient presentation and care 




All stakeholders (N=13) reported individual health impacts including impacts to both mental and 
physical health. With regard to mental health, a dual diagnosis of MA use disorder and an SMD was felt 
to be common “Naturally there is a lot of comorbidity”. Patients were thought to present with a variety 
of psychiatric syndromes, most commonly mania and psychosis and presented with more severe 
aggressive, impulsive and sexually inappropriate behaviors requiring higher levels of care. A significant 
consequence of MA use was cognitive decline. Patients who used MA were described to present with 
impaired attention, concentration, memory, executive function and social cognition. This was 
considered a contributor to poor insight and poorer outcomes as alluded to by one of the occupational 
therapists who reported:  
 
So, things like executive functioning, your ability to concentrate, your ability to pay attention 
whilst you are in a session. It impacts on their ability to take and receive what you are trying to do 
with them in your sessions. (Participant 12, occupational therapist) 
 
MA use was also reported to carry a risk to physical health “It leads to medical comorbidities which then 
makes the treatment more difficult”. A few (N=3) stakeholders highlighted that MA contributed to 
increased risky sexual behaviors among patients. The most common consequences discussed were HIV 
“Patients would say that they started using methamphetamine and they became HIV positive”; viral 
hepatitis “A patient I am seeing now used methamphetamine, became sexually disinhibited and 
contracted Hepatitis B” and unplanned pregnancies. All these sequelae were reported to increase illness 
severity and led to more treatment complexity.  
 
Second, MA use impacts not only on the individual user, but on their families. All stakeholders (N=13) 
believed that MA use and mental illness had a great impact for the families, the community and the 
patient’s social and occupational roles. This impact was believed to affect treatment outcomes as 
families fulfil an essential role in treatment and recovery. Consequences for families were believed to be 
far reaching and included effects to emotional, social, occupational and spiritual functioning with longer 
duration of substance use being linked to more significant negative outcomes. Stakeholders (N=6) 
believed that families were more empathetic towards patients diagnosed with an SMD in comparison to 
patients with a purely substance induced disorder. However, it was felt that, this understanding was 
impacted over time by ongoing non- compliance, recurrent admissions, ongoing family conflict, violence, 
aggression and illegal activities such as theft from the home. Eventually, stakeholders (N=5) reported 
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that families may withdraw support due to ongoing patient high risk behaviors which was reported to 
lead to negative consequences including homelessness and incarceration; which in turn negatively 
influences prognosis and recovery.  
 
Also, if they have been using for longer there is more kind of history of problems within their home 
environment. So, they have been using it for so long they then lost their job because they have been 
using, they then lost their families because they have been using it and now they move back to their 
families if they have been married. And of course, there is a lot of trouble there because then they 
start stealing, they start taking things from the house to go and get their drugs. They then cause 
other kind of conflict with their family within their home. So, yes, I suppose there is more violence 
and more family conflict opposed to a person that has got pure kind of psych. Also, the families are 
more understanding when there is a psych diagnosis attached to it. (Participant 12, Occupational 
Therapist) 
 
Lastly, MA use poses a significant impact to treatment and recovery. Several challenges to the treatment 
and recovery of patients living with a dual diagnosis were highlighted by stakeholders.  All stakeholders 
(N=13) described how MA use has a significant impact on admission rates in primary, secondary and 
tertiary settings. Stakeholders reported that “Before the methamphetamine epidemic psychiatric 
facilities really had a much smaller patient population with dual diagnosis” and “MA is one of the main 
drivers for admission to psychiatry”.  MA users were also perceived to relapse faster than non-
methamphetamine users. This was reported to lead to an increased number of high frequency service 
users returning for multiple admissions and increasing system burden. It was referred to as a “catch 22” 
as average length of stay has been decreased with patients being discharged sooner and this decreased 
the time available for treatments such as psycho education and motivational interviewing. 
 
The treating teams reported being negatively affected by ongoing system pressures. Some stakeholders 
(N=5) reported that patients who are admitted repeatedly may display deteriorating functioning and 
worsening circumstances which leaves stakeholders feeling that their inputs were inadequate despite 
giving their all amongst increasing service pressures.  
 
It is very disheartening…sometimes if feel like what I am doing is it even the right thing. 
Do I need to change the way I do things? Am I not doing things properly? (Participant 13, 
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occupational therapist)  
 
3. Available treatments for MA use and gaps in available services  
In this section existing treatments for MA use will be described and participants perceived challenges to 
these existing treatments. 
Existing Treatments 
According to most stakeholders (N=12), treatments available for MA use in the context of SMD varied 
widely across settings and depended on available staff, staff experience, available time and space, 
referral pathways and other resources. However, as highlighted by the stakeholders (N=2) only one 
facility responsible for the care and treatment of adult patients had a dedicated program; others relied 
on individual doctor, psychologist, social worker and occupational therapist input in both group, 
individual and family settings.  
 
All stakeholders (N=13) were engaging in some form of evidence- based techniques to address 
substance use. They would engage with patients both individually and in groups in a psychoeducational 
format to provide information regarding MA, its risks and its health and treatment impacts.  
Motivational interviewing was employed by several (N=6) stakeholders, mostly in individual sessions to 
explore and resolve ambivalence around MA use and encourage the desire to quit. All stakeholders 
(N=13) were using every available opportunity to use a motivational approach. This is demonstrated by 
an occupational therapist who commented: 
 
Why do they feel that it is a benefit for them to use; so, what does the substance do for them and 
what do they think if they were to stop it what do they think they could replace it with, so, levels of 
change to see where they at. (Participant 12, occupational therapist) 
 
Some stakeholders (N=4) employed simplified and easily digestible cognitive behavioral techniques with 
patients. These techniques included the identification and management of triggers and drug refusal 
skills. Role plays of these skills were found to be useful.  
 
It is identifying triggers, which is actually quite a complex one but we simplify it… They want to 
start but they struggle, and we will even have a conversation around “well when you walk pass the 
merchant on the way to the shop”, so we look at the concrete things that they can do in terms of 
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producing response to treat substance use. (Participant 11, occupational therapist) 
 
Several stakeholders (N=6) reported working with families for a variety of treatment related concerns 
including ongoing substance use. Family support was felt to be necessary to assist motivated patients in 
accessing further care and rehabilitation. 
 
I will have a family session with the patient after they had a motivational interviewing session to 
discuss what the outcome was. I will mention the services available to the family because more so 
than the patient accessing the services the family needs to be in the supportive role making sure 
that they go to the services. (Participant 9, social worker) 
 
All stakeholders (N=13) discussed that although patients receive other forms of social and occupational 
inputs aimed to facilitate recovery from both SMDs and substance use during admission, these time-
limited treatments are not enough to support recovery as stand-alone treatments. Comprehensive care 
should include engagement with community-based programs that focus on employment, education, 
recreation opportunities and family treatments once patients are discharged from hospital.  
 
There needs to be some planning for what happens after treatment, so developing social 
support systems and networks. (Participant 10, psychologist) 
 
Following improvement of SMD symptoms and discharge, some (N=4) stakeholders discussed referring 
patients to NGOs to allow for ongoing care.   
 
Because of the pressure it is not always possible to have more than three sessions… So, I do a lot of 
referrals to NGOs. (Participant 9, social worker) 
 
Stakeholders (N=4) reported that most patients access ongoing psychiatric care from day hospitals 
following discharge and raised concerns that  mental health teams at day hospitals may be stretched, 
substance treatment groups are not available, and medications may not be in stock. One psychiatrist 
highlighted that we need to address treatment of all mental disorders including substance use with the 




If more than 60% of patients in acute services had TB or HIV, we would be running very 
active services to address that… but up to 80% of patients are using substances and it is 
often not even recognized or addressed. (Participant 1, psychiatrist) 
 
One of the hospitals had a dedicated dual diagnosis program. This is an open, group- based outpatient 
program that relies mostly on psycho- education, motivational interviewing and relapse prevention skills 
that offered integrated substance use treatment and mental health treatment. It had been adapted 
overtime to meet service pressures. 
 
Perceived Challenges to Existing Treatments 
Stakeholders (N=13) described several challenges to existing treatments offered for MA use in the 
context of dual diagnosis. These challenges included treatment system factors, social factors and 
individual and illness factors.  
 
First, treatment systems refer both to the health system and to substance treatment facilities. 
Stakeholders (N=6) reported that health system pressures were felt at both district and tertiary level 
with ongoing bed pressures due to multiple factors. Stakeholders (N=6) held that this led to rapid 
discharge rates and impacted on time for treatments and time for recovery to baseline. According to the 
stakeholder working in a district hospital (N=1), district level services did not always have trained staff 
who were able to deliver substance treatments. Having skilled therapists, social workers and counsellors 
available at district would assist as reported by one psychiatrist who said: 
 
What would be very useful to help our meth problem at district level would be a cadre of people 
who are going to do motivational interviewing on everybody that we discharge. It would make a 
massive difference… I think it would also just make us feel a lot more hopeful about the vast 
majority of our patients. (Participant 4, psychiatrist) 
 
At tertiary level, stakeholders (N=5) reported that system pressures played a significant role and again 
led to limited time for substance treatments with increasing patient numbers. Stakeholders (N=5) felt 
that amongst themselves there was no specific dedicated space for substance treatment.  
 
Because of the pressure it is not always possible to have more than three sessions or more than 
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two sessions actually with the patient. (Participant 9, social worker) 
 
Cognitive sequelae of MA use was felt to impact significantly  on patient’s ability to actively participate 
in psychosocial rehabilitation treatments as reported by half the stakeholders (N=6). They elaborated 
that combination of decreased time for psychosocial treatments plus needing to adjust these 
treatments for patients with impaired cognition led to negative impacts on long term outcome. 
 
Half of the stakeholders (N=7) reported that following discharge of patients from hospital, 
patients may rapidly return to MA use and become intoxicated. These stakeholders held that 
this affects engagement with all further treatments, family engagement and wider socio-
occupational recovery.  
 
A few stakeholders (N=2) mentioned that treatment compliance may also be affected by medication 
side effects such as sedation, cognitive slowing and decreased libido. To compensate for this, it was 
reported that patients may also increase MA use to mitigate side effects which impacts on negatively 
impacts on recovery and leads to readmission. 
 
A few stakeholders (N=4) believed that external substance use treatment centers were highly variable; 
while some facilities were of good quality, others may not be evidence based. They reported that the 
available facilities often had long waiting lists and could be costly. They also shared concerns that 
although higher- functioning patients could benefit from traditional substance treatment programs such 
as 12 step programs; patients with residual symptoms or cognitive impairment could not assimilate the 
information and skills given. Some stakeholders (N=4) felt that patients with SMDs were possibly 
stigmatized by these facilities and other service users.  
 
There are patients with serious mental illness that attend SANCA or whatever and they do okay or 
Cape Town Drug Counselling Centre and they do okay but there are usually your more higher 
functioning. People with your severe residual symptoms would be disabling mental illness often do 
not fit in there and often do not do well there. (Participant 1, psychiatrist) 
 
Three stakeholders reported stigma at district and tertiary levels. Stigma is enacted by other patients, 
families and staff “Stigma is not limited to families. It is also there amongst doctors and nurses in 
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hospitals”. This stigma is may be more pronounced at district level amongst all non-mental health 
medical professionals working with mental health users and impacts on patient care and treatment 
options. Stakeholders felt that MA users may be more heavily stigmatized due to at risk behaviors and 
that staff hold less hope for a full recovery. 
 
So, I would guess that my non-psychiatric colleagues on hearing that patients is 
methamphetamine using gets treated in a much less kind and thoughtful way. (Participant 4, 
psychiatrist) 
 
Second, perceived social challenges described by the stakeholders included challenges within the family 
and the wider community. All stakeholders (N=13) explained that family factors play a significant role in 
patient care. They highlighted multiple key issues including that patients are often breadwinners and 
caregivers with significant responsibilities at home and therefore find it hard to attend rehabilitation 
centers or to remain longer in hospital. A second key issue was that, once patients are discharged, it is 
often costly to return to resourced, tertiary centers for follow- up. Lastly, stakeholders (N=7) explained 
that family support was key to motivating and supporting patients to access substance treatment 
services, but this may not occur if families are burnt out and tired of assisting. 
 
I think a lot of the time families are really at a loss, not necessarily because of the substance use...  
They really struggle to get along interpersonally. (Participant 6, psychiatrist) 
 
That comes up often in the family meetings that we have in the ward or when the family brings the 
patients. They kind of say, “Why should we help them? Why should we bring them to a clinic, they 
kind of deserve it. They choose to use Tik.”(Participant 3, psychiatrist) 
 
Stakeholders (N=5) reported that wider community factors pose a significant treatment challenge as 
patients are discharged back into communities where substances are readily available, where their 
peers and even families are using and where all the antecedents for substance use still exist. 
Stakeholders discussed (N=5) that treatment facilities are not always available at community level 
necessitating travelling to treatment facilities. Patients trying to access these facilities may encounter 




On a daily basis they are confronted with other active users and this becomes the big challenges 
for recovery. (Participant 10, clinical psychologist) 
 
Lastly, all stakeholders (N=13) held that illness related factors had significant impact on any individual or 
group-based substance treatments. The symptoms discussed included aggression, irritability, positive 
and negative psychotic symptoms and impaired cognition which all affected patient’s abilities to engage 
in treatment treatments. Of concern was impaired cognitive functioning due to SMD, MA or psychiatric 
medications. Stakeholders (N=3) felt that they needed to keep educational information simple, short 
and repetitive. Some stakeholders (N=4) reported that skills-based sessions such as CBT also required 
simplification, repetition, and practice. Of concern among stakeholders (N=6) was that the time- 
restrictions of an acute service severely limits the repetition leading to a lack of completeness of 
psychoeducation and CBT skills training. They reported that this led to patients leaving the service with 
limited substance treatment. Stakeholders (N=2) also reported that group interactions could prove 
challenging with patient’s being reluctant to engage with the task at hand or engaging in verbal conflict 
with each other. Patients may also feel stigmatized by their diagnosis and unwilling to engage in 
treatment.  
 
4. A Potential Screening and Brief Treatment for Methamphetamine Use 
among Patients with SMDs 
Under this section I shall discuss suggestions for a potential treatment; management of treatment 
challenges; and the treatment team and task sharing.  
Suggestions for a Potential Treatment 
The vast majority (N=11) of stakeholders felt that offering a brief treatment for patients with MA use in 
the context of dual diagnosis would be useful in addressing a precipitating and perpetuating factor of 
mental illness.  
 
I am treating people. I am treating their mood, their mania or their depression or their psychosis. 
And then they get better… And they go home and they get back to using…The methamphetamine 
is leading to the mania or the depression or the psychosis… But we are not doing anything to treat 
the underlying cause. (Participant 3, psychiatrist) 
 
One participant commented that “early again, is key” and that early intervention could be facilitated by 
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implementing routine screening for comorbid substance use among patients at initial presentation to 
outpatient clinics.  
 
The problem with people who present to in- patient services is that they have more severe 
problems anyway.  But I think there is definitely a place for community services, because 
community services allow people to be caught early, before the problems progressed to such a 
point that they need hospitalization. There is also less stigma in providing services at a community 
level versus going to a hospital. (Participant 10, psychologist) 
 
Stakeholders agreed that a possible brief treatment required several key features too be met:   
 
Accessibility and affordability 
Firstly, all stakeholders (N=13) agreed that a potential treatment should be easily accessible and 
affordable for patients. Most (N=9) stakeholders felt that such a treatment for patients with dual diagnosis 
should be offered at community level as this could allow for early treatment following screening before 
patients present to inpatient services. This was suggested as a way to improve patient outcomes and 
prevent admissions which would in turn take some pressure off in-patient psychiatric services. Most (N=9) 
stakeholders felt that integrating such a treatment into community mental health clinics would be most 
appropriate allowing for integrated care, easy referral, and accessible care. One stakeholder felt that 
perhaps such a treatment should be offered in community center which would be accessible but would 
be away from mental health services and may carry less stigma. Stakeholders (N=9) felt that integrated 
care at community level minimizes travel costs and service costs. Additionally, they believed this meant 
that community services would be available once patients are discharged from inpatient care and could 
be initiated once patients are recovering more from their psychiatric symptoms. One of the challenges 
identified with offering such a service at community level was that there are high levels of violence in 
communities, which limits access to care. A few (N=4) stakeholders suggested mirroring such a treatment 
in tertiary settings, mostly in pre- discharge units to allow easy access to initial care with down referral to 
community mental health services for ongoing care. This would also allow for repetition of the same 
message and skills. 
 






Second, several of the stakeholders (N=5), specifically the occupational therapists and social workers; 
agreed that a brief, time-limited and structured treatment would be useful. This group of stakeholders 
felt that sessions should be short, possibly limited to 15 or 20 minutes with multiple sessions of the 
same topic in a week, to accommodate for patients with cognitive impairment and to allow for 
reinforcing off information. They felt that the number of sessions could be limited. 
 
It should be a short-term treatment. If you are really looking to reach enough people, but it should 
be quite comprehensive in what it is able to offer. (Participant 9, social worker) 
 
Group versus individual treatment 
Third, half of the stakeholders (N=6) felt that both group treatments and individual treatments offered 
advantages and disadvantages that should be carefully considered. They discussed how groups had 
several advantages including allowing for more people to be reached; enabling patients to practice skills 
and to learn from each other’s experiences; and minimizing stigma as it demonstrates that other people 
have similar struggles. However, one stakeholder shared that groups bring group dynamics which must 
be carefully facilitated by keeping groups small and having more than one facilitator. Further, groups 
with patients of mixed educational and cognitive abilities need to be facilitated and adapted with care. 
The gender dynamics were also of concern among stakeholders and a suggestion was made that 
separate groups for men and women reduced gender dynamics and prevent exploitation of more 
vulnerable women. Stakeholders felt that individual sessions also offered advantages including more 
undivided attention from the person delivering the treatment which allows the patient to work at their 
own pace and for sensitive information to be discussed. However, stakeholders (N=-2) discussed that 
this is more labor intensive for the person delivering the treatment as it allows for fewer people to be 
reached together. An occupational therapist suggested that a combined approach may be most helpful. 
 
I think it would be nice to do a closed group because patients generally go through the phases of 
group development as well. So, if they start at the same time you would find that the cohesiveness 
and the sharing would happen at a later stage opposed to if you have an open group where you 
have random people joining all the time and now you need to open up about something really 




Inpatient versus outpatient approach 
Fourth, half of the stakeholders (N=6) felt that there were advantages to either an inpatient or an 
outpatient approach. The advantages of inpatient care that were discussed included allowing for 
treatments whilst the patient was still motivated and not surrounded by life stressors; however, it was 
believed that most patients would want to go home to their responsibilities instead of remaining in 
hospital longer. Multiple barriers have previously been discussed regarding inpatient treatment. Having 
a dedicated dual diagnosis inpatient unit was something that many stakeholders (N=6) suggested but 
they included that this could lead to multiple service challenges including available space, available staff, 
treatment costs and patient motivation to stay in hospital to the fore. Outpatient, community 
treatments have previously been discussed as being easily accessible, affordable, and allowing for early 
intervention. One suggestion was to offer a continuum of care, with initiation in hospital and 
continuation at community level.  
 
With the limited resources we have now, they get discharged before they are really ready for an 
brief treatment. So, what would be great is, if we could have another let us say four-week program 
or we could have more intense outpatient treatment or something else, in addition to what we 
offering now. (Participant 3, psychiatrist) 
 
Integration into existing services 
Fifth, all stakeholders (N=13) felt that any brief treatment should be integrated into existing treatment 
services allowing access to multiple aspects of service at once including medical plus social and 
occupational interventions. This would allow team members to offer a cohesive treatment approach for 
each patient. 
 
It has to be integrated. I do not think it could be standalone… I think the danger of that is that the 
individual is pathologized and it reinforces the notion of fixing the individual, taking the individual 
out of his or her setting, fixing him or her and putting him back… It just does not work. It is like taking 
a diseased tree, from a diseased forest trying to fix that tree, heal it and then put it back into the 




Components of treatment 
All stakeholders (N=13) agreed that over the course of a structured brief treatment, sessions should 
tackle different components including psychoeducation, motivational interviewing, cognitive and 
behavioral interventions plus family involvement. Although some of these components are utilized 
already by stakeholders, they felt that having a dedicated, structured treatment with dedicated role 
players would allow for cohesive treatment messages and space for additional treatment components 
not yet incorporated. The majority (N=12) of stakeholders stressed that these components could be 
structured to be simple and use creative formats. They also stressed that all potential treatment 
components should be kept simple and be reinforced. 
 
I think each treatment must have a couple of components.  I think it needs to educate people and 
provide them with information about their substance use and how it impacts on their mental 
health, if it is dual diagnosis treatment and the relationship between mental health and substance 
use. (Participant 10, psychologist) 
 
Psychoeducation was discussed by stakeholders (N=4) as being able to provide information regarding 
MA use, its effects, its impacts on mental illness and treatment compliance. They elaborated that risks 
to both mental and physical health need to be discussed. The mental health risks that they felt needed 
to be discussed included mental health symptoms such as irritability, decreased sleep, increased energy 
psychosis and aggression and the possibility of long term multifactorial cognitive impairment. They felt 
that patients should be able to gain an understanding of how MA use impacts treatment, compliance 
and prognosis; and how ongoing MA use may lead to long term consequences such as repercussions of 
families, functioning and need for recurrent admissions. Stakeholders (N=2) elaborated that given the 
physical health risks that MA poses, psychoeducation needs to include these risks and incorporate harm 
reduction tools to alleviate these risks. One such example mentioned was increased sex drive and risky 
sex practices linked to HIV; safe sex practices such as condoms and contraception need to be explored. 
One stakeholder suggested using engaging forms of media such as short, online videos to educate 
patients about the effects of substances. Stakeholders (N=4) agreed that psychoeducation should be 
delivered in an open, non- judgmental approach and could take creative formats such as pictures and 
videos. 
 
I think a lot of people do not actually have the right fact about their substance use and how it 
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impacts on their mental health.  I think it also needs to educate people about the recovery process 
particularly for methamphetamine use disorders because it is not about getting clean, it is about 
staying in recovery and that is how it takes time. (Participant 10, psychologist) 
 
Stakeholders (N=6) stated that motivational interviewing should be used to explore the ambivalence 
related to changing substance use. They felt that it could be offered as part of a brief treatment both in 
group and repeated in individual sessions which allows for both peer input to motivate for change and 
for individual repetition.  
 
Motivational Interviewing is also quite good in terms of harnessing patients’ motivation to change 
and allowing them to see the adverse and the positives of making change. (Participant 9, social 
worker) 
 
Suggested cognitive techniques included identification and management of triggers. Again, stakeholders 
(N=3) suggested using creative ways such as role play and writing to identify these.  
 
Then I think the treatment needs to help people to deal with all the factors that keep them using 
substances... Where coping skills are managed best and strategies for better emotional regulations 
are important.  And here the various tools versus the sort of cognitive and behavioral and more 
mindfulness-based strategies can be useful. (Participant10, psychologist) 
 
Behavioral treatments discussed by a few stakeholders (N=2) focused largely on relapse prevention and 
drug refusal techniques. 
Another behavioral treatment discussed by half of stakeholders (N=6) was contingency management. 
Traditionally this takes the form of rewarding patients for drug- free urine samples. The some 
stakeholders (N=4) felt that even attendance should be rewarded. This can be costly, but two 
stakeholders suggested creative forms of contingencies:  
 
A way to get patients to continue to come is to start a project together... So, if they are coming 
twice a week for four weeks at the end of it you have got something tangible to show. That would 





They all had a community garden. Everyone worked on the garden as they were doing their groups 
and if you wanted to take from the garden as well. (Participant 3, psychiatrist) 
 
A few stakeholders (N=2) discussed harm reduction techniques as a possible measure to address the 
harms of substance use concurrently with other treatments. They felt that patients did not always 
appreciate the physical risks of ongoing MA use and recurrent SMDs and associated treatments. 
Suggestions centered on contraception and HIV prevention. 
 
Some stakeholders (N=5) felt that it was important to identify peer support networks within 
communities for substance free behaviors. Additionally, aftercare in existing Twelve Step groups was 
suggested by one stakeholder. 
 
And then I think there needs to be some planning for what happens after treatment, so developing 
social support systems and networks and community involvement. (Participant 10, psychologist) 
 
A family session to address psychoeducation, discuss the treatment and how families could reinforce 
skills and provide any additional support was suggested by a few stakeholders (N=2). 
Management of Treatment Challenges  
All stakeholders (N=13) felt that all the existing challenges previously discussed applied to a brief 
treatment. They emphasized these additional challenges: 
Treatment costs 
First, most stakeholders (N=7) felt that attending a treatment could include multiple costs such as 
transport costs, cost of the program and time out of work. They suggested that this  could be managed 
by integrating treatments into communities or providing vouchers for transport. Obtaining funding for 
the treatment so that patients did not need to cover the cost was suggested. Additionally, incentivizing 
the treatment with vouchers or goods as a form of contingency management was thought to be useful. 
Offering tea and biscuits at the treatment was thought to be something that patients would appreciate. 
 
People do not have money to always attend so if you have transport you improve that, if you can 




Second, all stakeholders (N=13) believed that stigma posed a significant challenge and a contributor to 
ongoing use and non-compliance. They suggested multiple ways of addressing stigma during the 
treatment such as groups with patients with similar challenges and offering the treatment at neutral 
locations. One stakeholder suggested that addressing stigma needed to take place at a far higher level. 
Cognitive Impairment 
Third, cognitive impairment was thought to be a significant barrier. A few stakeholders (N=4) suggested 
that offering closed groups for patients with similar cognitive abilities would be ideal, allowing groups to 
work at different paces. They elaborated that content would need to be very simple and very skills 
based for patients with significant impairment. 
Lack of social supports 
Fourth, all stakeholders (N=13) felt that patients often relapsed because they returned to the same 
communities with the same triggers and no new roles or support. Some stakeholders (N=7) felt that 
treatments that targeted improved relationships and supportive functioning or supported employment 
would go a long way to prevent relapse. 
 
I think also finding meaning after substance use becomes challenging because many people come 
from very disadvantaged backgrounds and they have few other alternative sources.  So I think as a 
provider you have to become quite a creative and work quite carefully with the person to try and 
find sources that they can create a meaningful life beyond substances. (Participant 10, psychologist) 
 
Assertive Community Treatment 
Lastly, tertiary centers make use of assertive community treatment (ACT) approaches for patients with 
treatment resistant SMDs. In the Western Cape, these teams are limited by limited resources.  A few 
stakeholders (N=3) felt that if funding could be extended for ACT to reach more patients and to 
incorporate a brief treatment for substance use, this could be helpful. 
 
The Treatment Team and Task Sharing 
When asked who should be responsible for the treatment, it was agreed that a multidisciplinary team 
approach is key with team members who possess the necessary skills to work with patients and 
substance users. Various team members felt that they could contribute in different ways. Some 
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examples given were that doctors could provide simplified psychoeducation around neurobiological 
effects of drugs; social workers are skilled at working with families and occupational therapists teach 
skills well. 
 
Most stakeholders (N=8) felt that it would be possible to task share with community mental health 
nurses at community clinics, but that time and patient load may be prohibitive. Task sharing with lay 
counsellors was met with mixed responses. Some (N=7) it was felt to be possible with good supervision 






CHAPTER 5: DISCUSSION 
This study contributes to the growing evidence base of the need to integrate treatments for substance 
use, including MA, into treatments for patients with SMDs by exploring the views of key stakeholders on 
a brief treatment to address methamphetamine use among patients with a dual diagnosis. Findings 
suggest that 1) There is an urgent need to integrate treatments for MA use into current treatments for 
SMDs. 2) Existing treatments for MA use in patients with SMDs have significant treatment challenges 
within our context 3) Several proposals for the structure and integration of a potential treatment should 
be considered.  
Need to Integrate Treatment for MA into Existing Services 
To begin with, all stakeholders believed that there is an urgent need to integrate a treatment for MA use 
into current treatments for SMDs as they felt that MA is easily available with normalized use. Further, all 
stakeholders held that in patients with dual diagnosis, MA use leads to significant impacts to the 
individual, the family and to treatment and recovery treatment system.  
According to the stakeholders, individual impacts included impacts to mental and physical health. They 
felt that patients with SMDs and MA use presented with a variety of psychiatric symptoms, most 
commonly mania and psychosis. Further, symptoms of cognitive impairment, aggression, impulsivity and 
sexual disinhibition among patients with SMDs who used MA were reported to be more severe than 
patients who did not use MA. This was consistent with international data which reveals that MA use 
results in multiple psychiatric sequelae including different psychiatric syndromes (Rawson et al., 2002) 
with symptoms of impulsivity and aggression (Maxwell, 2005). A South African study has shown 
increased aggression in MA users with and without psychotic symptoms, suggesting that MA use is the 
driver of aggression (Uhlmann, Ipser, Wilson, & Stein, 2018). Cognitive impairment due to MA use has 
received significant attention in the literature and includes impairment of multiple cognitive domains 
including attention and concentration, learning and memory, working memory, verbal fluency, executive 
function and social cognition (Barr et al., 2006b; Potvin et al., 2018). This cognitive impairment 
significantly affects treatment of MA use even amongst people without dual diagnosis (Potvin et al., 
2018). Any potential treatment for patients with SMDs and MA use would need to cognizant of cognitive 
sequelae. Stakeholders also reported physical health complications among MA users, most commonly 
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HIV and other infections. These comorbidities were found to further impact patient presentation, illness 
severity and treatment complexity.  
Physical consequences discussed by stakeholders included the risk of infections such as HIV and viral 
hepatitis; and unplanned pregnancies. Previous literature has focused on comorbidity of MA use and 
HIV due to an increase in risky sexual practices such as increased libido and impaired social judgment in 
MA users (Simbayi et al., 2006). Further, substance use environments may be associated with risky 
behaviors and substance use may lead to with sexual violence (Browne & Wechsberg, 2010). Given the 
high prevalence of HIV in South Africa of 12,2% (Zuma et al., 2016); it would be important when 
designing an treatment for patients with dual diagnosis who use MA in South Africa to include 
information around HIV and other infections and their transmission and prevention.  This approach has 
shown promising findings in previous studies (Browne & Wechsberg, 2010).  
Within this study, stakeholders reported that MA use also impacted families and wider socio- 
occupational roles with reported impacts including emotional, social, occupational and spiritual effects 
with ongoing negative effects leading to worsening outcomes. Substance use leads significant mental, 
physical, emotional and financial effects on families (Groenewald, 2018). A study conducted in Cape 
Town, South Africa examined the experiences of the caregivers of youth using MA (Asante & Lentoor, 
2017). In that study, caregivers reported negative emotions including shame, fear, and self- blaming 
with additional disruption to family functioning and financial strain (Asante & Lentoor, 2017). A second 
qualitative study conducted in Cape Town, South Africa among MA users described emotional and 
physical violence within the families of MA users. MA use was found to impact on family social and 
economic functioning. And lastly, MA led to disrupted parenting of children of MA users (Watt et al., 
2014). Despite these effects, family interventions are not always integrated into substance use 
treatment programs. Support services may be of great value in enabling families to cope with 
psychosocial stressors and to strengthen family relationships (Groenewald, 2018). This in turn would 
support recovery for the individual substance user. Incorporating family inputs into a potential brief 
treatment is therefore vital.  
Further, MA was reported to have significant impacts to treatment and recovery with increased 
admission rates, high frequency users and negative impacts on treating teams. A previous study 
conducted in the Western Cape, South Africa found that substance use, including MA use, was one of 
several contributors to medication non- adherence, symptom recurrence and leads to readmissions 
(Botha et al., 2010).  
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Given that MA carries significant impacts to mental and physical health, to family and broader socio-
occupational roles, and to treatment and recovery as reported by stakeholders; addressing MA use in 
the form of a brief treatment has the potential to decrease HIV incidence, decrease severity of mental 
disorder symptoms and presentation, improve family relationships and reduce readmissions. 
Challenges to Existing Treatments 
Despite this clear need for services, existing treatments for MA use in patients with SMDs are met with 
significant treatment challenges within the South African context. Treatment of MA and other substance 
use among patients with SMDs is highly variable across settings and dependent on availability of staff, 
experience of staff and potential time and space within pressured and resource- limited environments. 
Within the South African context, multiple local studies have found these treatment challenges for 
substance use to include negative perceptions of treatment, easy availability of substances with 
normalized use and motivations to quite with a lack of awareness of treatment options. (Meade et al., 
2015). Further barriers to treatment included fragmented service delivery; poor capacity and other 
infrastructural concerns; and limited resource allocation to treatments which limits affordable and 
accessible services particularly amongst disadvantaged communities(Bronwyn Myers et al., 2008). These 
barriers were even more pronounced amongst women (B Myers et al., 2011); and among black and 
colored populations (Bronwyn Myers, 2013). 
 
International literature has shown that dual diagnosis is best managed with integrated modified 
multimodal approaches (Drake & Mueser, 2000; Subodh, Sharma, & Shah, 2018) including 
psychoeducation (Chilton, Crone, & Tyson, 2018), motivational interviewing (Subodh et al., 2018), 
cognitive behavioral techniques such as contingency management and relapse prevention (Subodh et 
al., 2018), family therapy (Drake & Mueser, 2000); (Richards, Doyle, & Cook, 2009) and twelve step 
supports (Bogenschutz, Geppert, & George, 2006). In South Africa, when available, treatment strategies 
make use of several of these evidence-based treatment modalities including psycho education, 
motivational interviewing, modified cognitive behavioral approaches, family intervention and referral to 
NGOs and peer support systems. 
Stakeholders agreed that these existing treatments have multiple perceived challenges. First, 
stakeholders stated unequivocally that significant service pressures existed in both district and tertiary 
inpatient setting; these impacted on the time available for treatments and recovery. In South Africa and 
globally, deinstitutionalization has led to a decrease in inpatient admission beds available and has 
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shifted the primary focus of psychiatric admissions to stabilization of symptoms as opposed to recovery 
from SMDs with limited time available for inpatient rehabilitative treatments (Botha, Coetzee, Koen, & 
Niehaus, 2018), (Vigod et al., 2013). This has led to a decrease in average length of stay for patients 
which in turn leads to early readmissions and contributes to the development of high frequency service 
users (Botha et al., 2010) with up to one quarter of patients being readmitted 3 months after their initial 
discharge (Docrat et al., 2019). This stretches existing financial resources available for mental health 
significantly which impacts financial resources available to contribute to and strengthen existing mental 
health care services especially at district and primary care level (Docrat et al., 2019).   Second, 
stakeholders felt that not all staff within district and tertiary inpatient services possessed the necessary 
skills to manage dual diagnosis, this was felt to be particularly true of non- mental health staff in district 
hospitals. Internationally, it has been stated that not all doctors, including psychiatrists, are thought to 
be adequately trained to assess and treat patients with SUD (Renner, Quinones, & Wilson, 2005). Within 
South Africa, there have been multiple studies reporting difficulties with treatment of severe mental 
disorders within general hospital settings, including staff expertise (Petersen & Lund, 2011). Treating 
patients with dual diagnosis requires further clinical expertise including appropriate training in 
knowledge of SUD (Renner et al., 2005), motivational interviewing, cognitive behavioral therapy and 
psychopharmacology (Renner Jr, 2004). These skills may not be available in all settings. Third, 
stakeholders repeatedly focused on the treatment challenges posed by cognitive impairment and its 
effects on patients’ abilities to internalize and practice treatments. The extent of cognitive impairment 
due to MA has previously discussed and has a significant impact on treatment in people without a dual 
diagnosis (Potvin et al., 2018). Stakeholders had several suggestions for adapting treatments for patients 
with cognitive impairment and these would need to be carefully implemented and monitored. Fourth, 
stakeholders highlighted that following discharge patients return to communities where MA is easily 
available and return to preexisting stressors which leads to relapse. MA is widely available within the 
Western Cape and poses significant mental health treatment burden (Pasche & Myers, 2012) with 
approximately one third of MA users presenting with comorbid mental disorders (Akindipe et al., 2014). 
Fifth stakeholders felt that patients may manage treatment side effects and mental health symptoms 
with MA use. Sixth, given the limited times available for treatments within inpatient facilities, patients 
were referred to external treatment centers which were thought to be highly variable in their approach 
to MA use in dual diagnosis. This is in keeping with international trends where MA use may be to self- 
medicate SMD symptoms of psychotic, mood, anxiety and other disorders (Gouzoulis-Mayfrank et al., 
2017). Lastly, families may be burnt out and refuse to provide ongoing care and support for patients. A 
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potential treatment for patients with MA use in the context of SMDs would need to take that into 
account. As previously discussed, MA use carries significant emotional, social and economic burdens for 
families (Asante & Lentoor, 2017); (Watt et al., 2014). 
A Potential Integrated Treatment 
Most stakeholders believed that a brief treatment for MA use in the context of SMDs would be a 
beneficial step in managing a significant contributor to mental illness. Screening and brief intervention 
and referral to treatment (SBIRT) for substance use is an approach designed to deliver an early 
treatment for people with substance use (McCance-Katz & Satterfield, 2012). Brief intervention is aimed 
at developing insight into substance use and to develop motivation to change (McCance-Katz, 2012). 
Referral to treatment is provides more extensive care for individuals screened with more severe 
substance use (McCance-Katz, 2012). Brief treatments exist along the SBIRT continuum as an 
intermediary between brief intervention and referral to treatment (Babor, 2017). Brief treatment is 
aimed at patients with higher severity of substance use and may requires more resources (Babor, 
2017). Typically, brief treatment takes the form of a structured intervention comprising of five to 
twelve individual sessions drawing from motivational and cognitive- behavioral treatment 
modalities (Babor, 2017).   
 Within the Western Cape, several SBIRT programs have been implemented with success in a variety of 
settings.  In one study, a brief treatment was offered to patients presenting to a district hospital 
(Sorsdahl, Stein, Weich, Fourie, & Myers, 2012). This study demonstrated that offering SBIRT at district 
hospitals was accessible to populations groups not presenting to traditional treatment services; that 
SBIRT was both feasible and acceptable to patients presenting to district hospitals; and SBIRT was 
effective in reducing substance use (Sorsdahl et al., 2012). A second study examined the feasibility of 
integrating SBIRT for substance use and depression into routine antenatal care (Katherine Sorsdahl et 
al., 2015). This study demonstrated that integration of SBIRT into antenatal care was both feasible; 
SBIRT was effective to address depression and smoking but did not alter alcohol and other drug use 
significantly (Katherine Sorsdahl et al., 2015). Although staff found this program barriers, they identified 
some implementation challenges including increased workload and limited time; lack of clearly 
delineated referral pathways for women with severe depression;  and perceived limited disclosure of 
maternal substance use (Katherine Sorsdahl et al., 2015). A third randomized control trial investigated 
the integration of SBIRT within the emergency centers (K Sorsdahl, Dan J Stein, et al., 2015). This study 
demonstrated that SBIRT is feasible within emergency centers and effective at reducing substance use 
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among high risk individuals (Sorsdahl et al., 2012). Further research was felt to be needed to investigate 
if these effects were sustained long term (K Sorsdahl, Dan J Stein, et al., 2015). A fourth study examined 
delivery of treatments for common mental disorder such as alcohol use disorder and depressive 
disorders by community health workers within primary care (Bronwyn Myers et al., 2019). This study 
demonstrated further feasibility and acceptability of a task shared mental health treatment for patients 
with common mental disorder at primary care level (Bronwyn Myers et al., 2019). These studies 
therefore demonstrate several valuable lessons to be considered when developing a brief treatment for 
MA use among patients with SMDs. However, significantly, none of these studies focused on SMDs and 
this is an immense gap that requires careful attention.  
Stakeholders proposed several components and prerequisites for that treatment. First, screening for 
substance use, including MA, should be conducted for all patients at initial and subsequent 
presentations, whether as an inpatient or an outpatient. Integrating screening and brief treatments for 
substance use into community services allows for early, timeous treatment within international cohorts 
(Babor et al., 2017). Second, a brief treatment for MA use would need to be accessible and affordable 
and may be best placed into community clinics. However, there was thought to be value in offering a 
duplicate brief treatment within general hospital and tertiary inpatient services to allow for repetition of 
the same message at multiple levels of care. As previously discussed, brief treatments have been 
demonstrated to be acceptable, feasible and effective in studies conducted in multiple settings within 
the Western Cape (Sorsdahl et al., 2012); (Katherine Sorsdahl et al., 2015); (K Sorsdahl, Dan J Stein, et 
al., 2015); (Bronwyn Myers et al., 2019). Integration of care into primary level care has been met with 
challenges such as resource limitations (Tomlinson et al., 2016) and would require strengthening the 
system including staff training and support to be successful (Thornicroft et al., 2018).Third, a brief time- 
limited and structured treatment would be useful with short sessions repeated several times over the 
course of the week to accommodate for patients with cognitive impairment. Given the impact of 
cognitive impairment on treatments of MA use, studies have examined a variety of cognitive training 
techniques; these have included computerized delivery of treatments that are simplistic, repetitive and 
adaptable (Sofuoglu, DeVito, Waters, & Carroll, 2013). It may be possible to combine similar ideas into a 
potential brief treatment for example simple written messages and diagrams that are step by step and 
can be worked through during individual and group sessions. Fourth, treatments that offered individual 
components, but group reinforcement were thought to be beneficial for practicing skills and to reach 
multiple patients simultaneously; care would need to be taken to facilitate these groups paying 
attention to individual cognitive abilities and particularly vulnerable patients. Peer persuasion groups 
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are described in the literature as groups for patients with SMDs and substance use (Kofoed & Keys, 
1988). These groups are facilitated and use a motivational format to allow group members to argue for 
substance change (Kofoed & Keys, 1988). These have been effective in decreasing substance use 
(Kofoed & Keys, 1988). There is less evidence regarding other modalities as group treatments for 
patients with dual diagnosis. Building a dedicated peer persuasion group into a ward structure could 
work synergistically with a brief treatment. Fifth inpatient or outpatient approaches were thought to be 
equally advantageous; one suggestion was a continuum of care with initiation as an inpatient and 
continuation at community level, but this would require manpower. However, the literature suggests 
that an integrated approach within both inpatient and outpatient programs between mental health and 
substance treatment teams is the most effective in managing dual diagnosis (Bogenschutz et al., 2006). 
Sixth, the brief treatment must be integrated into existing services. Implementation and barriers to this 
have been discussed above. Lastly, sessions would need to be multimodal and include components of 
psychoeducation, motivational interviewing, harm reduction techniques, cognitive- behavioral including 
contingency management and relapse prevention, plus family involvement. International literature has 
shown that dual diagnosis is best managed with integrated modified multimodal approaches (Drake & 
Mueser, 2000; Subodh et al., 2018).  But these would need to be simple, creative and integrated into 
existing programs.  
 
Stakeholders also felt that a potential brief treatment may face potential challenges and proposed some 
adjustments and adaptations. First, treatments may be costly. This could be mitigated by meeting 
transport costs, offering contingency rewards or offering treatments within communities. From a 
systematic review, contingency management for patients with dual diagnosis, were found to be an 
effective treatment (Drake et al., 2008).  Second, stigma was perceived as a significant barrier; this could 
be addressed within groups or by offering the treatment within neutral, community locations. Stigma 
may need to be addressed at a broader level. Third, cognitive impairment as already been mentioned, 
proposed ways to manage this include simplified content, smaller groups or individual sessions that 
were short and repetitive. Fourth, the wide availability of MA in communities was a significant 
challenge. Broader treatments such as employment and recreational opportunities were proposed as 
solutions. From local literature, people may initiate MA use due to boredom, thrill seeking and lack of 
recreational and occupational opportunities (Hobkirk, Watt, Myers, Skinner, & Meade, 2016).Creating 
access to these opportunities on a broader sociopolitical level may assist to decrease MA use. Lastly, 
ACT approaches were suggested, however more resources would be required. 
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 Stakeholders held that different members of the treatment team could offer different components of a 
brief treatment, this would allow for the maximizing of existing skills and time. Generally, a task sharing 
approach was recommended. Suggestions were that doctors could provide simplified psychoeducation 
sessions workers are skilled at working with families and occupational therapists could teach skills such 
as relapse prevention. Although task sharing to community nurses was considered, they would need to 
be consulted to determine the acceptability of this approach.  Task sharing to lay counsellors was met 
with mixed feelings, some thought that this would be possible with enough supervision; whilst others 
felt that lay counsellors may not have the prerequisite skills to managed patients with dual diagnosis. 
Task sharing allows for sharing of tasks from highly specialized individuals to other individuals with less 
specialized training (Hoeft, Fortney, Patel, & Unützer, 2018). This is an approach from global mental 
health care that has been implemented within resource limited settings to improve delivery of mental 
health treatments (Hoeft et al., 2018). It allows for a limited number of specialized individuals to work 
collaboratively with existing community resources and maximizes the reach of mental health treatments 
within a population (Hoeft et al., 2018). Within a South African context, deinstitutionalization of mental 
health care and the need for reciprocal up- scaling of care available at primary care level has led to the 
investigation of task- sharing services with community health workers and lay counsellors to allow for 
delivery of effective mental health services (Spedding, Stein, & Sorsdahl, 2014).  A mental health training 
program for community health workers conducted within the Western Cape found that evidence- based 
mental health training improved attitudes, knowledge, and confidence among community health 
workers (Sibeko et al., 2018). The impact of this training on patient care requires further investigation 
(Sibeko et al., 2018). A thematic analyses of nine studies conducted in South Africa focused on task 
sharing with non-specialist health care workers for delivery of evidence- based treatments for common 
mental disorders, including depression and substance use, has demonstrated effectiveness of task- 
shifting treatments (Spedding et al., 2014).  However, none of the nine studies focused on SMDs. Given 
the evidence for task sharing for management of common mental disorders, it is important to 
investigate task sharing for SMDs as this may assist in addressing an important treatment gap (Hanlon et 
al., 2016). Further investigation is therefore needed regarding feasibility, acceptability and efficacy of 
task shared treatment for SMDs within South Africa. 
Limitations 
This study had several limitations: First, our sample of health care personnel were predominately from 
specialist inpatient psychiatric hospitals in the Western Cape and is not necessarily representative of all 
health care providers in all settings. The degree to which these findings can be generalized to other 
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settings is unknown. The Western Cape in one of the better resourced provinces with higher rates of 
SMDs and MA use than others, other settings may differ markedly. Second, this study focused on the 
opinions of health care providers. Before integrating a brief treatment into current practice, it would be 
beneficial to understand the perspective of the potential service users and their needs. Third, the 
importance of family participation in the treatment was highlighted by stakeholders. When planning a 
treatment, it would be of paramount importance to obtain perspectives of families and caregivers of MA 
users with dual diagnosis.  Fourth, there may have been information biases. Given the nature of the 
interviewer, participants may have given biased opinions reflecting what they thought that the 
interviewer wanted to hear. The researcher was known to and a former colleague of several 
stakeholders which may have led to further disclosure of information biases. 
Implications 
MA use among patients with SMDs carries significant impacts to patients, their families, the health 
system and the treating team. Current treatments are met with significant barriers. A potential brief 




CHAPTER 6: CONCLUSIONS 
From this study there is evidence of an urgent need to integrate treatments for MA use into current 
treatments for SMDs as MA is easily accessible with high rates of MA use among the general population 
and people with mental disorders. Furthermore, existing treatments for MA use in patients with SMDs 
have significant treatment challenges within our context. The majority of stakeholders who participated 
in this study felt that integrating a brief intervention into existing treatments for patients with SMDs 
who used MA was necessary 
 
Several prerequisites and components to the treatment were proposed including routine screening for 
substance use; the treatment would need to be accessible and affordable; there are advantages to 
individual or group formats employing a variety of evidence based techniques and adjusting for ongoing 
psychiatric symptoms such as cognitive impairment. The treatment could be integrated into treatment 
as usual at multiple levels with multidisciplinary team members sharing treatment delivery.  
 
An important next step in planning a treatment would be to understand the needs of patients and their 
families and to understand the perspective of potential providers at community level before formulating 
a brief treatment that takes the suggestions of stakeholders, potential participants and their families 
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